Zhihong Li

29PUBLICATIONS
36CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer diagnosisApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Oct 11, 2025
Dual Targeting of m7G tRNA Modification and Histone Acetylation using Carrier-Free Nano-Epidrugs to Evoke Osteosarcoma Chemosensitization.

Lin Qi, Wenchao Zhang, Changrong Shi

|Jun 06, 2025
A Dual Approach with Organoid and CRISPR Screening Reveals ERCC6 as a Determinant of Cisplatin Resistance in Osteosarcoma.

Ruiling Xu, Sai Zhu, Wenchao Zhang

|Feb 28, 2025
RFWD3 Reprograms Nucleotide Metabolism Through PHGDH to Induce Chemoresistance In Osteosarcoma.

Wenchao Zhang, Chi Yin, Lin Qi

|Nov 20, 2024
Cooperative blockade of FLT3 and ALK synergistically suppresses growth of osteosarcoma.

Wenchao Zhang, Lin Qi, Haodong Xu

|Oct 30, 2024
Omics-Enhanced Nanomedicine for Cancer Therapy.

Lin Qi, Zhihong Li, Jianping Liu

|Oct 16, 2024
ImmuneApp for HLA-I epitope prediction and immunopeptidome analysis.

Haodong Xu, Ruifeng Hu, Xianjun Dong

Pageof 5

Frequent Collaborators

6 joint publications

Chao Tu

3 joint publications

Haodong Xu

3 joint publications

Binfeng Liu

3 joint publications

Lin Qi